Crispr Theraptc’s (CRSP) “Buy” Rating Reiterated at Barclays PLC
Crispr Theraptc (NASDAQ:CRSP)‘s stock had its “buy” rating reiterated by analysts at Barclays PLC in a report released on Friday. They currently have a $29.00 price target on the stock. Barclays PLC’s price target would indicate a potential upside of 54.75% from the stock’s previous close.
A number of other analysts have also recently weighed in on the company. Cann started coverage on Crispr Theraptc in a research report on Monday, July 17th. They set a “market perform” rating for the company. SunTrust Banks, Inc. started coverage on Crispr Theraptc in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 price objective for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research report on Tuesday, July 18th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $23.08.
Shares of Crispr Theraptc (NASDAQ:CRSP) traded down 1.88% on Friday, reaching $18.74. The company had a trading volume of 128,660 shares. The firm’s market capitalization is $760.68 million. Crispr Theraptc has a 52 week low of $11.63 and a 52 week high of $25.00. The company’s 50-day moving average price is $18.56 and its 200 day moving average price is $17.82.
Crispr Theraptc (NASDAQ:CRSP) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.06. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The company had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $3.29 million. The firm’s revenue was up 350.0% compared to the same quarter last year. On average, analysts expect that Crispr Theraptc will post ($2.43) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Crispr Theraptc’s (CRSP) “Buy” Rating Reiterated at Barclays PLC” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/09/crispr-theraptcs-crsp-buy-rating-reiterated-at-barclays-plc.html.
In other Crispr Theraptc news, Director Kurt Von Emster sold 88,011 shares of the stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $19.79, for a total transaction of $1,741,737.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tyler Dylan-Hyde sold 15,000 shares of the stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $18.57, for a total value of $278,550.00. Following the sale, the insider now directly owns 167,727 shares of the company’s stock, valued at $3,114,690.39. The disclosure for this sale can be found here. Insiders have sold a total of 827,921 shares of company stock valued at $15,063,254 over the last ninety days. 39.98% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. IHT Wealth Management LLC purchased a new position in shares of Crispr Theraptc during the 1st quarter worth approximately $110,000. Wells Fargo & Company MN raised its stake in shares of Crispr Theraptc by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after buying an additional 6,560 shares in the last quarter. ARK Investment Management LLC purchased a new position in shares of Crispr Theraptc during the 2nd quarter worth approximately $206,000. Vanguard Group Inc. purchased a new position in shares of Crispr Theraptc during the 2nd quarter worth approximately $273,000. Finally, Monashee Investment Management LLC raised its stake in shares of Crispr Theraptc by 208.7% during the 1st quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares in the last quarter. 23.90% of the stock is owned by institutional investors and hedge funds.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.